ERBB2 and breast cancer: Although this therapy was designed to target breast cancer metastases, the data demonstrated the safety and feasibility of intraventricular HER2 CAR T cell administration and showed encouraging signals of clinical activity (51), thus setting the stage for studies that combine HER2-CAR T cells with other immune-modulatory approaches to enhance their expansion and persistence (51, 52).